Enrico Ruffini1, Wentao Fang2, Francesco Guerrera3, James Huang4, Meinoshin Okumura5, Dong Kwan Kim6, Nicolas Girard7, Andrea Billè8, Souheil Boubia9, Ayten Kayi Cangir10, Frank Detterbeck11, Conrad Falkson12, Pier Luigi Filosso3, Giuseppe Giaccone13, Kazuya Kondo14, Maurizio Infante15, Marco Lucchi16, Mirella Marino17, Edith M Marom18, Andrew G Nicholson19, Andreas Rimner4, Ramon Rami-Porta20, Hisao Asamura21. 1. University of Torino, Thoracic Surgery, Torino, Italy. Electronic address: enrico.ruffini@unito.it. 2. Shanghai Chest Hospital, Jiaotong University Medical School, Thoracic Surgery, Shanghai, People's Republic of China. 3. University of Torino, Thoracic Surgery, Torino, Italy. 4. Memorial Sloan Kettering Cancer Center, Thoracic Surgery, New York, New York. 5. Osaka Toneyama Medical Center, Thoracic Surgery, Osaka, Japan. 6. Asan Medical Center, Thoracic Surgery, Seoul, Republic of South Korea; University of Ulsan College of Medicine, Thoracic Surgery, Seoul, Republic of South Korea. 7. Institut Curie, Medical Oncology, Paris, France. 8. Guy's Hospital, Thoracic Surgery, London, United Kingdom. 9. CHU Ibn Rochd, Thoracic Surgery, Casablanca, Morocco. 10. Ankara University Faculty of Medicine, Thoracic Surgery, Ankara, Turkey. 11. Yale University School of Medicine, Thoracic Surgery, New Haven. 12. Queen's University in Kingston, Radiation Oncology, Ontario, Canada. 13. Weill Cornell Medicine, Medical Oncology, New York, New York. 14. Tokushima University, Department Oncological Medical Services, Tokushima, Japan. 15. University and Hospital Trust, Thoracic Surgery, Verona, Italy. 16. Azienda Ospedaliero-Universitaria Pisana, Thoracic Surgery, Pisa, Italy. 17. IRCCS Regina Elena National Cancer Institute, Pathology, Rome, Italy. 18. University of Texas MD Anderson Cancer Center, Houston, Texas; University of Tel Aviv, the Chaim Sheba Medical Center, Radiology, Tel Aviv, Israel. 19. Royal Brompton and Harefield NHS Foundation Trust and National Heart and Lung Institute, Imperial College, Pathology, London, United Kingdom. 20. Hospital Universitari Mutua Terrassa, Terrassa, Spain, and Network of Centers for Biomedical Research in Respiratory Diseases Lung Cancer Group, Thoracic Surgery, Terrassa, Spain. 21. Keio University, Thoracic Surgery, Tokyo, Japan.
Abstract
OBJECTIVES: The International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee-Thymic Domain conducted a web-based cross-sectional survey to assess the acceptance of the TNM thymic staging system in the thoracic community. METHODS: A 50-item, web-based questionnaire was circulated among the members of the major thymic organizations worldwide from September to December 2018. The survey consisted of six sections (general information; overall perception of the TNM system; pretreatment staging; T category; N category; and perioperative treatments). RESULTS: In total, 217 responses were collected from 37 countries in four continents. The TNM classification was considered useful by 78% of the responders (N = 169); the Masaoka-Koga staging system was being used by 87% of the responders (N = 189). With regard to the T category, most responders (mostly surgeons) felt that the capsular and mediastinal pleural involvements should be considered separate T categories. As for the N category, 48% of the responders (N = 105) used the International Thymic Malignancies Interest Group/International Association for the Study of Lung Cancer thymic nodal map, and lymph node dissection (N1/N2) was performed for 50%/21% thymomas and 66%/41% thymic carcinomas. While analyzing the results by the three continents (Europe, Asia, and Americas), responders in Asia were found to report the largest use of the TNM system, the greatest attention to the N category, and the best participation in international thymic databases. CONCLUSIONS: The survey indicates that the Union for International Cancer Control/American Joint Committee on Cancer TNM stage classification of thymic tumors is gaining acceptance among the scientific community. The present results will guide the work of the Staging and Prognostic Factors Committee-Thymic Domain for the revision of the ninth edition of the TNM stage classification of thymic tumors.
OBJECTIVES: The International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee-Thymic Domain conducted a web-based cross-sectional survey to assess the acceptance of the TNM thymic staging system in the thoracic community. METHODS: A 50-item, web-based questionnaire was circulated among the members of the major thymic organizations worldwide from September to December 2018. The survey consisted of six sections (general information; overall perception of the TNM system; pretreatment staging; T category; N category; and perioperative treatments). RESULTS: In total, 217 responses were collected from 37 countries in four continents. The TNM classification was considered useful by 78% of the responders (N = 169); the Masaoka-Koga staging system was being used by 87% of the responders (N = 189). With regard to the T category, most responders (mostly surgeons) felt that the capsular and mediastinal pleural involvements should be considered separate T categories. As for the N category, 48% of the responders (N = 105) used the International Thymic Malignancies Interest Group/International Association for the Study of Lung Cancer thymic nodal map, and lymph node dissection (N1/N2) was performed for 50%/21% thymomas and 66%/41% thymic carcinomas. While analyzing the results by the three continents (Europe, Asia, and Americas), responders in Asia were found to report the largest use of the TNM system, the greatest attention to the N category, and the best participation in international thymic databases. CONCLUSIONS: The survey indicates that the Union for International Cancer Control/American Joint Committee on Cancer TNM stage classification of thymic tumors is gaining acceptance among the scientific community. The present results will guide the work of the Staging and Prognostic Factors Committee-Thymic Domain for the revision of the ninth edition of the TNM stage classification of thymic tumors.
Authors: Fabrizio Minervini; Laura Boschetti; Michael Gregor; Mariano Provencio; Virginia Calvo; Peter B Kestenholz; Savvas Lampridis; Davide Patrini; Pietro Bertoglio; L Filipe Azenha; Consolato M Sergi; Gregor J Kocher Journal: Gland Surg Date: 2021-11
Authors: Mirella Marino; Alexander Marx; Lucia Anemona; Libero Lauriola; Philipp Ströbel; Hans Konrad Müller-Hermelink Journal: Pathologica Date: 2021-10